Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS (2016) J Clin Oncol 34: 2098-106 Urological cancer: walking the tightrope of survival and quality of life with ADT. Resnick MJ (2013) Nat Rev Clin Oncol 10: 307-8 Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW, Matusik RJ (2015) Oncogene 34: 3700-10 Androgen receptor-mediated repression of novel target genes. Prescott J, Jariwala U, Jia L, Cogan JP, Barski A, Pregizer S, Shen HC, Arasheben A, Neilson JJ, Frenkel B, Coetzee GA (2007) Prostate 67: 1371-83 Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, Carver B, Chang K, Hannon GJ, Sawyers CL (2012) PLoS One 7: e34414 The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M (2005) J Urol 174: 547-52; discussion 552 Fluorescent detection of Zn(2+)-rich vesicles with Zinquin: mechanism of action in lipid environments. Snitsarev V, Budde T, Stricker TP, Cox JM, Krupa DJ, Geng L, Kay AR (2001) Biophys J 80: 1538-46 Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. Lloyd A, Penson D, Dewilde S, Kleinman L (2008) Prostate Cancer Prostatic Dis 11: 153-9 Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M, Penson D (2005) Urology 66: 835-9 Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator. Mattmann ME, Yu H, Lin Z, Xu K, Huang X, Long S, Wu M, McManus OB, Engers DW, Le UM, Li M, Lindsley CW, Hopkins CR (2012) Bioorg Med Chem Lett 22: 5936-41
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.